Industry
Biotechnology market research
Asset assessment and commercial strategy for biotech innovators from preclinical to launch.
HealthcareMarketResearch runs biotechnology market research for global leaders, challengers and investors. Our 5,000+ researchers include practising clinicians, procurement leaders, payers and former executives from the biotechnology industry.
Studies combine expert calls, qualitative interviews and quantitative surveys, so you can size the opportunity, understand stakeholders and plan go-to-market with confidence.
Topics we research
- Target product profiles
- Asset valuation
- Partnering strategy
- Orphan indications
Relevant services
At a glance
Biotechnology market research at a glance
The audiences, methods and timelines a typical biotechnology study runs on.
- Audiences
- Chief scientific and medical officers, translational and clinical development leads, principal investigators, specialist pharmacists, BD and licensing leads, HTA assessors and investor diligence teams
- Typical methods
- Expert calls, target product profile reaction interviews, KOL mapping, advisory boards and primary diligence sprints
- Research focus
- target product profiles · asset valuation · partnering strategy · orphan indications
- Geography
- 100+ Indian cities, metro and tier 2, plus global peer benchmarks
- Expert matching
- 24–48 hours from a confirmed brief
- Fieldwork window
- 5–10 business days for most interview and survey studies
- Core outputs
- Attribute trade-off summaries, TPP implications, addressable population logic, named KOL lists and an assumption table your model can use
- Regulatory context
- Work is framed around FDA, EMA and CDSCO development milestones and orphan designation pathways, under EphMRA and BHBIA codes.
Scope, sample and timings are confirmed in writing before fieldwork starts.
Why teams commission it
Decisions biotechnology research supports
Each brief starts from the decision it has to inform, so the readout answers the question your team is actually facing.
Target product profile
Which efficacy, safety, dosing and administration attributes clinicians trade off, and which claims a TPP has to win on.
Indication sequencing
Which indication to lead with, where unmet need is sharpest, and which orphan or niche populations give the cleanest entry.
Asset valuation inputs
Prescriber intent, addressable population logic and switching behaviour, primary-sourced so diligence models rest on evidence.
Partnering and licensing
How prospective partners, licensees and acquirers read the asset, and what evidence moves a deal conversation forward.
Pricing and access feasibility
Payer and HTA expectations on comparators, endpoints and budget impact, before a pricing corridor is committed to.
Launch readiness
Treatment-centre capability, referral routes and the field model a first commercial team actually needs.
Stakeholders
Who we reach in biotechnology
We recruit the people who make and influence the decision — not only the easiest audience to find. Every expert is screened for recency of practice and conflicts of interest.
Science and development
- Chief scientific and chief medical officers
- Translational and clinical development leads
- Principal investigators at academic and trial centres
- Regulatory affairs and CMC leads
Treating and prescribing
- Specialist consultants in the target indication
- Hospital and specialty pharmacists
- Clinical nurse specialists running infusion and trial visits
- Clinical directors at centres of excellence
Capital and access
- Business development and licensing leads
- Venture, growth and private equity diligence teams
- Payer medical directors and HTA assessors
- Patient advocacy and rare disease group leads
How it runs
A biotechnology research programme, stage by stage
Senior researchers at our Pune, Maharashtra, India headquarters design, moderate and analyse every study.
- 01
Frame the asset question
We agree the development or investment decision in play, then build screeners and guides around the indication, comparators and TPP attributes that matter.
Scoped in writing
- 02
Specialist recruitment
We identify investigators, treating specialists and former industry leads from our 5,000+ network, screening for recency of practice, trial involvement and conflicts.
24–48 hours
- 03
Depth interviews and expert calls
Senior moderators run expert calls, profile reaction exercises and treatment pathway discussions, with off-label and adverse event handling built into the guide.
5–10 business days
- 04
Synthesis for the decision
Findings are coded into attribute trade-offs, assumption tables and risks, then debriefed with your development, BD or diligence team.
Report and debrief
Compliance
Standards every biotechnology study runs under
Compliance is designed into the screener and the guide, not bolted on at the end.
Research codes
biotechnology guides follow EphMRA, BHBIA and Insights Association standards, including adverse event and off-label handling.
Regulatory framing
Work is framed around FDA, EMA and CDSCO development milestones and orphan designation pathways, under EphMRA and BHBIA codes.
Data protection
Recruitment, transcripts and data files are handled under GDPR, HIPAA and India's DPDP Act, with pseudonymised outputs.
Conflict screening
Every expert is screened for employer restrictions, confidentiality obligations and conflicts of interest before a session is confirmed.
FAQs
Biotechnology market research questions
What is biotechnology market research?+
Biotechnology market research is primary research with the scientists, investigators, treating specialists, payers and investors who determine whether an asset succeeds. HealthcareMarketResearch covers target product profiles, asset valuation, partnering strategy and orphan indications through expert calls, interviews and surveys.
Can you reach investigators and specialists for a preclinical or early-stage asset?+
Yes. Our 5,000+ network includes practising specialists, principal investigators and former industry executives, screened for recency of practice and conflicts. Expert calls usually start within 24–48 hours of a confirmed brief.
How do you test a target product profile?+
We put profile attributes — efficacy, safety, dosing, administration and monitoring — in front of treating specialists and ask them to trade off against current standard of care, then repeat the exercise with payers to see which attributes survive access scrutiny.
Do you support investor and licensing diligence?+
Yes. We run primary diligence for venture, growth and private equity teams and for business development groups, sourcing prescriber intent, treatment pathway and competitor assumptions that a valuation model can be built on.
How is off-label and adverse event handling managed?+
Guides are written to EphMRA, BHBIA and Insights Association guidance, with adverse event reporting routes and off-label question rules agreed before fieldwork. Data is handled under GDPR, HIPAA and India's DPDP Act.
Coverage
Where we run biotechnology research in India
Studies are designed and analysed at our Pune, Maharashtra, India headquarters, with recruitment and fieldwork across 100+ Indian cities — metro, tier 2 and tier 3.
All industries
Explore the other 24 healthcare segments
Grouped by the kind of organisation or therapy area you work in, so you can find the neighbouring page quickly.
Life sciences companies
Therapy areas
Care delivery, payers and technology
Have a healthcare question that needs real answers?
Brief us today and talk to a verified expert this week.